Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an announcement.
Ondine Biomedical and Mid Yorkshire Teaching NHS Trust have been shortlisted for the 2026 Excellence in Healthcare Partnership Awards for their collaboration using Ondine’s Steriwave nasal photodisinfection technology to reduce surgical site infections in orthopaedic patients. The partnership, which has already earned a separate national technology award nomination, demonstrated a 71% reduction in hip surgery infections and zero infections in knee surgeries over six months at the Trust’s hospitals, delivering both better patient outcomes and cost savings. The recognition underscores the growing role of non-antibiotic, resistance-free infection-prevention solutions in addressing NHS priorities such as patient safety, antimicrobial stewardship and efficiency, and comes as Steriwave adoption expands across major English hospitals and multiple clinical settings amid rising concern over antibiotic resistance and poor compliance with traditional nasal decolonisation methods.
The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Spark’s Take on GB:OBI Stock
According to Spark, TipRanks’ AI Analyst, GB:OBI is a Underperform.
Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.
To see Spark’s full report on GB:OBI stock, click here.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specialising in light-activated antimicrobial therapies, known as photodisinfection, aimed at preventing and treating infections, including those caused by multidrug-resistant organisms. Its CE-marked Steriwave nasal photodisinfection system is approved for nasal decolonisation in multiple countries outside the US, where it holds special regulatory designations and is in clinical trials, and the company is also developing additional photodisinfection-based therapies for indications such as chronic sinusitis, ventilator-associated pneumonia and burns.
Average Trading Volume: 184,138
Technical Sentiment Signal: Sell
Current Market Cap: £49.89M
For a thorough assessment of OBI stock, go to TipRanks’ Stock Analysis page.